SCHEMBL31005784

SCHEMBL31005784

COc1ccc(CNc2ccc3c(c2)CN(C)CC3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ NPC1 O15118 3/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ ALDH1A1 P00352 5/20 0.52
▸ KDM4E B2RXH2 4/20 0.52
▸ GAA P10253 4/20 0.52
▸ DRD1 P21728 4/20 0.51
▸ DRD5 P21918 4/20 0.51
▸ TP53 P04637 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ UTS2R Q9UKP6 1/20 0.48
▸ POLB P06746 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47
▸ DRD2 P14416 3/20 0.47
▸ DRD3 P35462 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17797500 0.81 MAPT (0.49) MAPTRAB9ANPC1L3MBTL1LMNA
SCHEMBL17797492 0.80 MAPT (0.48) MAPTRAB9ANPC1L3MBTL1LMNA
SCHEMBL17797510 0.79 TMPRSS2 (0.53) MAPTRAB9ANPC1L3MBTL1LMNA
SCHEMBL17797642 0.79 TMPRSS2 (0.53) MAPTRAB9ANPC1L3MBTL1LMNA
SCHEMBL29843474 0.77 DRD1 (0.79) DRD1DRD5DRD2DRD3DRD4
SCHEMBL4317508 0.77 DRD1 (0.79) DRD1DRD5DRD2DRD3DRD4
SCHEMBL8128442 0.77 NPC1 (0.70) MAPTRAB9ANPC1ALDH1A1DRD1
SCHEMBL17797522 0.75 ESR2 (0.56) MAPTRAB9ANPC1LMNAALDH1A1
SCHEMBL17797535 0.74 MAPT (0.53) MAPTRAB9ANPC1L3MBTL1LMNA
SCHEMBL11823744 0.74 DRD1 (0.85) DRD1DRD5DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619407-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 Curadev Pharma Ltd (GB) 2025-09-24 — — EP disclosed
US-20250282794-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 CURADEV PHARMA LTD (GB) 2025-09-11 — — US disclosed
WO-2024105363-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 CURADEV PHARMA LTD (GB) 2024-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282794-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 PDXK, PGK1, CMPK1 MAPT 4306/4885RAB9A 3722/4885NPC1 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback